Get started
Author

Maria Chiriboga Yerovi

Observed names: Chiriboga Yerovi, Maria, Maria P. Chiriboga Yerovi, Maria P. Chiriboga-Yerovi
ORCID: 0009-0000-0563-8669
Observed ORCID: 0009-0000-0563-8669
OpenAlex ID: A5067760338
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response
2024 · Mason J. Webb, Thanich Sangsuwannukul, et al. · Nature Communications · 57
T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy
2025 · Thanich Sangsuwannukul, Benjamin Kendall, et al. · Molecular Therapy · 2
Immunodominant antiviral T cell responses outcompete immuno-subdominant antitumor responses to reduce the efficacy of oncolytic viroimmunotherapy
2025 · Richard Vile, Benjamin Kendall, et al. · Research Square · 2
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome
2024 · Richard Vile, Jose Pulido, et al. · Research Square · 1
Immunodominant Antiviral T-cell Responses Outcompete Antitumor T-cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy
2026 · Benjamin L. Kendall, Olivia Y. Liseth, et al. · Cancer Research
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome
2026 · Alex Chen, Jose S. Pulido, et al. · Cancer Immunology Research
AIRE-modified B16 H-2Kb Immunopeptidomics
2026 · Alex Chen, Jose S. Pulido, et al. · Figshare
Locl-03 Intratumoral Delivery of Conditionally Replicative Human Adenovirus 657 Expressing the Immune Co-stimulator Cd40l (crad657-cd40l) as a Potentially Promising Treatment for Recurrent Pediatric High Grade Glioma
2022 · Mason Webb, Soumen Khatua, et al. · Neuro-Oncology Advances
Works count: 9
Citation count: 62
H-index: 2
I10-index: 1
Year
Topic
Type